Investors of Sun Pharmaceutical Industries Ltd, are jittery over the silence and lack of communication from market regulator, SEBI. SEBI has neither accepted nor denied the whistleblower’s allegations against the company’s corporate misgovernance. In December, Business Standard reported that SEBI is probing the country's leading drugmaker for corporate misgovernance. Shares of the company tanked 26%, causing wealth destruction of nearly Rs 24,500 crore in a span of 10 days. On Jan 17, Moneylife reported another whistleblower complaint made against the company with SEBI. On January 17 and 18, the stock tanked 23% eroding investor wealth worth Rs 20,100 crore.